A Four-Pillar Framework integrating Delivery Systems, Immune Safety, CMC and Manufacturing Readiness, and biomarker-guided Clinical Design is proposed to support coordinated optimization across biological, pharmaceutical, and clinical dimensions rather than isolated improvement of individual delivery parameters.
Qian-Qian Liu, Li-Wei Jia, Xin Meng et al.· Current Drug Delivery· 0 citations
C. nutans demonstrates significant medicinal potential, and future research priorities should include bioactivity-guided isolation of novel metabolites, validated in vivo mechanistic studies, pharmacokinetic and metabolomic profiling, and the implementation of standardized Phase I/II clinical trials and veterinary eval...
Wen-Xuan Si, Xin-Yue Sun, Yuan-Bin Han et al.· Frontiers in Pharmacology· 0 citations
ADMET analysis indicates that orientin has promising pharmaceutical properties and provides a basis for future research focusing on structural optimization, metabolic transformation, and in vivo evaluation.
Liwei Jia, Yu Zhong, Bao Xu et al.· Archives of Biochemistry and...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.